Targeting senescence to delay progression of multiple sclerosisOost, W., Talma, N., Meilof, J. F. & Laman, J. D., Nov-2018, In : Journal of Molecular Medicine. 96, 11, p. 1153-1166 14 p.
Research output: Contribution to journal › Review article › Academic › peer-review
Multiple sclerosis (MS) is a chronic and often progressive, demyelinating disease of the central nervous system (CNS) white and gray matter and the single most common cause of disability in young adults. Age is one of the factors most strongly influencing the course of progression in MS. One of the hallmarks of aging is cellular senescence. The elimination of senescent cells with senolytics has very recently been shown to delay age-related dysfunction in animal models for other neurological diseases. In this review, the possible link between cellular senescence and the progression of MS is discussed, and the potential use of senolytics as a treatment for progressive MS is explored. Currently, there is no cure for MS and there are limited treatment options to slow the progression of MS. Current treatment is based on immunomodulatory approaches. Various cell types present in the CNS can become senescent and thus potentially contribute to MS disease progression. We propose that, after cellular senescence has indeed been shown to be directly implicated in disease progression, administration of senolytics should be tested as a potential therapeutic approach for the treatment of progressive MS.
|Number of pages||14|
|Journal||Journal of Molecular Medicine|
|Early online date||18-Sep-2018|
|Publication status||Published - Nov-2018|
- Aging, Senolytics, Glia, Neurodegeneration, Inflammation, Autoimmunity, CENTRAL-NERVOUS-SYSTEM, VASCULAR ENDOTHELIAL-CELLS, CD4(+)CD28(-) T-CELLS, BLOOD-BRAIN-BARRIER, CELLULAR SENESCENCE, SECRETORY PHENOTYPE, CNS REMYELINATION, SENOLYTIC DRUGS, PRECURSOR CELLS, CANCER CELLS